Main Article Content



Since 2002, there has been a record ofCoronavirus disease outbreak caused by SARS-CoV,MERS-CoV, as well as the novel SARS-CoV-2, the causalagent of the Coronavirus Disease 2019 that broke outin Wuhan, China in December the same year and hassince become widespread across several countries andcontinents leading to thousands of deaths More than 180 vaccine candidates, based on several different platforms(Fig. vaccine platform used for SARS-CoV-2 vaccine developement), are currently in development against SARS-CoV-2(57) (Fig. overview of the SARS-CoV-2 vaccine development landscape). TheWorld Health Organization (WHO) maintains a working document(57)that includes most of the vaccines in development and is available at Clinical trials are evaluating COVID-19 vaccines in tens of thousands of study participants to Generate the scientific data and other information needed to determine safety and effectiveness These clinical trials are being conducted by manufacturers according to rigorous standards.

MERS-CoV, SARS-CoV-2, human par influenza, influenza virus

Article Details

How to Cite
PATEL, A., RAY, B., HUSSAIN, A., & BEHERA, P. K. (2021). COVID 19: RECENT VACCINE AND VACCINE UNDER TRAIL. Asian Journal of Advances in Medical Science, 3(4), 272-289. Retrieved from
Review Article


Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323:1061-1069.


World Health Organization. Pneumonia of unknown cause–China. Emergencies preparedness, response, Disease outbreak news, World Health Organization (WHO); 2020.

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. “COVID-19 infection: origin, transmission, and characteristics of human coronaviruses,” Journal of Advanced Research. 2020;24:91–98.View Available:,%20transmission,%20and%20characteristics%20of%20human%20coronaviruses&author=M.%20A.%20Shereen&author=S.%20Khan&author=A.%20Kazmi&author=N.%20Bashir&author=&author=R.%20Siddique&publication_year=2020

Zhang HW, Yu J, Xu HJ, et al. “Corona virus international public health emergencies: implications for radiology management,” Academic Radiology. 2020;27(4):463–467, View at: Available:

Kan B, Wang M, Jing H, Xu H, Jiang X, Yan M, et al. Molecular evolution analysisand geographic investigation of severe acute respiratory syndromecoronavirus-like virus in palm civets at an animal market and on farms. J Virol. 2005;79(18):11892–900.

Zheng BJ, Guan Y, Wong KH, Zhou J, Wong KL, Young BWY, et al. SARS-relatedvirus predating SARS outbreak, Hong Kong. Emerg Infect Dis. 2004;10(2):176.

Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 2008;133(1):74–87.

Annan A, Baldwin HJ, Corman VM, Klose SM, Owusu M, Nkrumah EE, et al.Humanbetacoronavirus 2c EMC/2012–related viruses in bats, Ghana andEurope. Emerg Infect Dis. 2013;19(3):456.

Paden C, Yusof M, Al Hammadi Z, Queen K, Tao Y, Eltahir Y, et al. Zoonoticorigin and transmission of Middle East respiratory syndrome coronavirus inthe UAE. Zoonoses Public Health. 2018;65(3):322–33.

Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, et al. Evidence supporting azoonotic origin of human coronavirus strain NL63. J Virol. 2012;86(23):12816–25.

Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, Chen H, et al. Geneticcharacterization of Betacoronavirus lineage C viruses in bats reveals markedsequence divergence in the spike protein of pipistrellus bat coronavirus HKU5in Japanese pipistrelle: implications for the origin of the novel Middle Eastrespiratory syndrome coronavirus. J Virol. 2013;87(15):8638–50.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation andepidemiology of 2019 novel coronavirus: implications for virus origins andreceptor binding. The Lancet; 2020.

Chan JF-W, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster ofpneumonia associated with the 2019 novel coronavirus indicating person-topersontransmission: a study of a family cluster. Lancet; 2020.

Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomiccharacterization of the 2019 novel human-pathogenic coronavirus isolatedfrom a patient with atypical pneumonia after visiting. Wuhan. EmergingMicrobes & Infections. 2020;9(1):221–36.

Beniac DR, Andonov A, Grudeski E, Booth TF, Logunov DY. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet

Available: (2020).


Luk HK, Li X, Fung J, Lau SK, Woo PC. (Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infection, Genetics and Evolution. 2019;71:21-30.

Coronavirinae in Viral Zone. (accessed on 05 February 2019).

Subissi L, Posthuma CC, Collet A, Zevenhoven-Dobbe JC, Gorbalenya AE, et al. One severe acute respiratory syndrome coronavirus proteincomplex integrates processive RNA polymerase and exonuclease activities. Proc. Natl. Acad. Sci. USA. 2014;111, E3900–E3909.

Zhao L, Jha BK, Wu A, Elliott R, Ziebuhr J, Gorbalenya AE, Silverman RH, Weiss SR. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell host & microbe. 2012;11(6): 607–616.

Barcena M, Oostergetel GT, Bartelink W, Faas FG, Verkleij A, Rottier PJ, Koster AJ, Bos BJ. Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(2):582–587. 17. Neuman BW, Adair BD, Yoshioka C, Quispe JD, Orca G, Kuhn P, Milligan RA, Yeager M, Bucheier MJ. Supramolecular architecture of severe acuterespiratory syndrome coronavirus revealed by electron cryomicroscopy. Journal of virology. 2006;80(16):7918–7928. 18.

Peele KA, Srihansa T, Krupanidhi S et al. Design of Multiepitope vaccine candidate against SARS-CoV-2: a in-silico study. Journal of Biomolecular Structure & Dynamics. 2020; 1.

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novelcoronavirus spike protein by a SARS coronavirus-specific human monoclonalantibody. bioRxiv; 2020.

Vara V. Coronavirus outbreak: The countries affected. 11 MARCH 2020;

Available from:

Shi Y, Yi Y, Li P, Kuang T, Li L, Dong M, et al. Diagnosis of severe acuterespiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsidantibodies in an antigen-capturing enzyme-linked immunosorbent assay. JClinMicrobiol 2003;41 (12):5781–2.

Dong N, Yang X, Ye L, Chen K, Chan EW-C, Yang M, et al. Genomic and proteinstructure modelling analysis depicts the origin and infectivity of 2019-nCoV, anew coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv; 2020.

Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan2019 novel coronavirus (2019-nCoV), December 2019 to January 2020.Eurosurveillance. 2020;25(4).

Anonymous. Vaccines for Your Children. Diseases You Almost Forgot about (Thanks to Vaccines). Centre for Diseases Control and Prevention; 2020.

Available from: Parents/diseases/forgot-14-diseases.html.

Aryal S. Vaccines-introduction and Types with Examples Online Microbiology Notes by SagarAryal; 2020. March 29, 2018. Updated April 9.


Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster ofpneumonia associated with the 2019 novel coronavirus indicating person-topersontransmission: a study of a family cluster. Lancet; 2020.

Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;2:1804-20.

Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth,D., Goettsche M, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J. Virol. 2010; 84:11336–11349.

Yin Y, Wunderink RG. MERS SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130-137.

Peiris JSM, Lai ST, Poon L, et. al. Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet. 2003;361(9366):1319-1325.

Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD,Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012;367:1814–20.

World Health Organization. Pneumonia of unknown cause–China. Emergencies preparedness, response, Disease outbreak news, World Health Organization (WHO); 2020.

Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et all Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med; 2020.

Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan2019 novel coronavirus (2019-nCoV), December 2019 to January 2020.Eurosurveillance. 2020;25(4).

Parry J. China coronavirus: cases surge as official admits human to humantransmission. British Medical Journal Publishing Group; 2020.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamicsin Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med; 2020.

Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing2019-nCoV epidemic threat of novel coronaviruses to global health—The latest2019 novel coronavirus outbreak in Wuhan, China. International Journal ofInfectious Diseases. 2020;91:264–6 .

Huang Y. The SARS epidemic and its aftermath in China: a political perspective.Learning from SARS: Preparing for the next disease outbreak; 2004;116–36.[80] Holmes KV. SARS coronavirus: a new challenge for prevention and therapy. J ClinInvestig 2003;111(11):1605– 9.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patientsinfected with 2019 novel coronavirus in Wuhan China. The Lancet; 2020

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation andepidemiology of 2019 novel coronavirus: implications for virus origins andreceptor binding. The Lancet; 2020.

Perlman S. Another decade, another coronavirus. Mass Medical Soc; 2020.

Bolles M, Donaldson E, Baric R. SARS-CoV and emergent coronaviruses: viraldeterminants of interspecies transmission. Current Opin Virol. 2011;1(6):624–34.

Vara V. Coronavirus outbreak: The countries affected. 11 MARCH 2020;Available from:

Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516-27.


Seven days in medicine: 8-14 Jan 2020. BMJ. 2020; 368-132.31948945.

Imperial College London. Report 2: estimating the potential total number of novel coronavirus cases in Wuhan City, China. Jan. disease-analysis/news--wuhan-coronavirus; 2020.

European Centre for Disease Prevention and Control data.Geographical distribution of 2019- nCov cases. Available online: (accessed on 05 February 2020).

World Helath Organization, nCoV Situation Report-22 on 12 February, 2020. source/coronaviruse /situation-reports/, 2019.

Gralinski L, Menachery V. Return of the Coronavirus: 2019- nCoV, Viruses, 2020;12(2):135.11. Chen Z, Zhang W, Lu Y et al.. From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of Early Epidemic and Prediction of Future Trends.: Cell Press; 2020.

Draft Landscape of COVID-19 Candidate Vaccines. Available: item/draft-landscape-of-covid-19-candidate-vaccines (WHO, accessed 26 September 2020).

Wang H, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, withpotent protection against SARS-CoV-2. Cell 182, 713–721.e9 ; 202.

Gao Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369L:77–81.

Zhang YJ, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine inhealthy adults aged 18–59 years: report of the randomized, double-blind, andplacebo-controlled phase 2 clinical trial. Preprint at (2020).This was the second study to show immunogenicity of an inactivated SARS-CoV-2vaccine in humans.

Talon J. et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl Acad. Sci. USA. 2000;97:47309–4314.

Broadbent, A. J. et al. Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the pandemic H1N1 influenza virus, in ferrets. Vaccine. 2016;34:563–570.

Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033–1036.

Chen WH, et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminium hydroxide induces protective immunity and reduces immune enhancement.

Preprint at


Chen J. et al. Receptor-binding domain of SARS-CoV spike protein: soluble expression in E. coli, purification and functional characterization. World J. Gastroenterol. 2005;11:6159–6164.

Amanat F. et al. Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model.

Preprint at (2020).

Mercado NB, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature

Available: (2020).

Keech C, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med; 2020.

Available: This is the first study to report immunogenicity of a recombinant spike vaccine in humans.

Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348–E7357. This study shows that coronavirus spike proteins can be stabilized by changing two amino acids in S2 to pralines; 2017.

Corbett KS. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.Nature Available: (2020).

Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369:1501–1505.

Zhu FC. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised,first-in-human trial. Lancet. 2020;395:1845–1854. This paper reports a first-in-human study with an AdV5-based vaccine candidate

against SARS-CoV-2.

Zhu FC, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488.

Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. A key study demonstrating immunogenicity of the ChAdOx1 nCoV-19 vaccine in humans.

Graham SP. et al. Evaluation of the immunogenicity of prime–boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines. 2020;5:69.

van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.

Nature (2020).

Case JB. et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe. 2020;28:465–474. e4.

Sun W, et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate; 2020.

Preprint at

Rohaim MA, Munir M. A scalable topical vectored vaccine candidate against SARS-CoV-2. Vaccines. 2020;8:472.

Sun W, et al. A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine; 2020.

Preprintat 2020.07.30.229120

Vogel AB, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 2018;26:446– 455.

Laczkó D, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity; 2020.


Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med; 2020.

Available: (2020).

Lu J, et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020;30:936– 939.

Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N. Engl. J. Med; 2020.

Available: This is the first report on the immunogenicity of Moderna’s mRNA SARS-CoV-2 vaccine candidate in humans.

Mulligan MJ, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature

Available: (2020).